文献速递临床血液与体液质量管理与危急值

基于中国室间质评与生物学变异数据的凝血因子检测允许总误差规范比较分析

Comparative analysis of allowable total error specifications for coagulation factor assays utilizing China National External quality assessment scheme data and biological variation data.
PubMed 文献 · Clin Chim Acta · 2025-01-16

该研究分析中国全国室间质评计划中1381家实验室的28408条凝血因子检测结果,按参考区间分层建立浓度依赖性允许总误差规范,并与生物学变异导出的总误差比较。结果显示无分析物能满足生物学变异导出的最佳总误差,8个参数达到期望标准,仅低水平FXI未达最低标准。建议按浓度水平和当前技术可及性分别设定总误差规范。

要点

  • 凝血因子检测总误差规范应按浓度水平分别设定。
  • 无分析物满足生物学变异导出的最佳总误差标准。
  • 低浓度凝血因子受分析物浓度影响显著。

核心结论

  • 凝血因子检测允许总误差规范应依据不同浓度水平和当前检测技术可及性分别建立。
  • 设定总误差规范还需考虑临床需求与不同地区监管标准。

研究设计与样本

  • 分析中国全国室间质评计划数据,共1381家实验室的28408条结果。
  • 按参考区间分层室间质评数据以建立浓度依赖性总误差规范。
  • 以参与者80%最佳结果定义「当前技术水平」总误差,并与生物学变异导出总误差比较。

主要发现

  • 无分析物能满足生物学变异导出的最佳总误差。
  • FII、FVIII、FX在高和低水平以及FVII、FIX在高水平共8个参数达到期望标准。
  • 仅低水平FXI未达到最低标准。
  • 分析物浓度显著影响实验室性能,尤其对低浓度凝血因子。

关键数值与推荐

  • 「当前技术水平」总误差定义为参与者80%最佳结果对应的总误差。
  • 8个参数达到期望标准:FII、FVIII、FX(高和低水平),FVII、FIX(高水平)。
  • 低水平FXI未达到最低标准。

临床怎么用

  • 检验科应按凝血因子浓度水平分别设定和评估允许总误差。
  • 设定总误差规范时应结合临床需求、地区监管标准及当前技术可及性。
  • 总误差规范需定期更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is necessary and challenging to establish reasonable and feasible total error specifications for coagulation factor assays for quality control and assessment. The aim of this study is to establish new total error specifications for coagulation factor assays by combining External Quality Assessment data with reliable biological variation data. METHODS: Data from China National External Quality Assessment Scheme (28,408 results from 1,381 laboratories) were analyzed, stratifying External Quality Assessment data by reference intervals to establish concentration-dependent total error specifications. A "state-of-the-art" total error was defined at 80% best results of the participants. Then these specifications were compared with biological variation-derived total error to determine recommended total error specifications for different concentration levels. RESULTS: None of the measurands could meet biological variation-derived optimum total error. Eight parameters (FII, FVIII, FX at both high and low levels; FVII and FIX at high level) reached the desirable criteria. Only FXI at low level can't met the minimum criteria. CONCLUSIONS: The establishment of total error specifications for coagulation factor assays should be set separately according to different concentration levels and attainability of current testing technologies. Setting total error specifications should also consider clinical requirements and regulatory standards across different regions. Analyte concentration significantly influences laboratory performance, particularly for low-concentration coagulation factors. Total error specifications need updated periodically in the further. ABBREVIATIONS: Tea, allowable total error; BV, biological variation; SOTA, state of the art; EQAS, External quality assessment schemes; ME, measurement error; RIs, reference intervals; BIVAC, Biological Variation Data Critical Appraisal Checklist; QIs, quality items; EFLM, European Federation of Clinical Chemistry and Laboratory Medicine; APS, analytical quality specifications; ISO, International Organization for Standardization; EQA, External quality assessment; PT, proficiency testing; RCPA, Royal College of Pathologists of Australasia; RfB, Reference Institute for Bioanalytics; ECAT, External Quality Control for Assays and Tests.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Xu C, Du Z, Hu G, et al. Comparative analysis of allowable total error specifications for coagulation factor assays utilizing China National External quality assessment scheme data and biological variation data. Clin Chim Acta. 2025. PMID: 39826574. doi:10.1016/j.cca.2025.120141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。